Hollis Eden Pharmaceuticals Inc. (HEPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (122)	11/26/2001 1:47:15 PM
From: Jim Oravetz	Read Replies (1) of 138

Hollis-Eden:Immune Regulating Hormone Pdt Study Positive SAN DIEGO -- Hollis-Eden Pharmaceuticals Inc. (HEPH) found that HE2200, an immune regulating hormone drug candidate, was generally well tolerated by the patients in a Phase I clinical study. In a press release Monday, the company said HE2200 was subcutaneously administered in healthy young and elderly adult volunteers. Hollis-Eden also received clearance from the Food and Drug Administration to begin a similar Phase I human clinical trial with HE2200 using a buccal tablet formaulation. Preclinical studies with HE2200 have indicated the compound has the potential to provide benefit in a variety of settings of immune dysregulation including inflammatory bowel disease, age-related loss of immunity and radiation-induced immune suppression. Hollis-Eden plans to conduct Phase II clinical studies related to one or more of these areas. Company Web site: holliseden.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next